These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7893930)

  • 1. Large-scale preparation and biochemical characterization of a new high purity factor IX concentrate prepared by metal chelate affinity chromatography.
    Feldman PA; Bradbury PI; Williams JD; Sims GE; McPhee JW; Pinnell MA; Harris L; Crombie GI; Evans DR
    Blood Coagul Fibrinolysis; 1994 Dec; 5(6):939-48. PubMed ID: 7893930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Removal and inactivation of enveloped and non-enveloped viruses during the purification of a high-purity factor IX by metal chelate affinity chromatography.
    Roberts PL; Walker CP; Feldman PA
    Vox Sang; 1994; 67 Suppl 1():69-71. PubMed ID: 8091741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Properties of a highly purified human plasma factor IX:c therapeutic concentrate prepared by conventional chromatography.
    Burnouf T; Michalski C; Goudemand M; Huart JJ
    Vox Sang; 1989; 57(4):225-32. PubMed ID: 2617959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Large-scale production and properties of a solvent-detergent-treated factor IX concentrate from human plasma.
    Michalski C; Bal F; Burnouf T; Goudemand M
    Vox Sang; 1988; 55(4):202-10. PubMed ID: 3265237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Blood protein technological industrial developments as a mirror of fundamental studies bgy the Institute of Biochemistry of the Ukrainian National Academy of Sciences].
    Volkov GL; Andrianov SI; Horoshnykova TV; Borysevych OS; Gavryliuk OS
    Ukr Biokhim Zh (1999); 2000; 72(4-5):109-21. PubMed ID: 11200439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity.
    Gray E; Tubbs J; Thomas S; Oates A; Boisclair M; Kemball-Cook G; Barrowcliffe TW
    Thromb Haemost; 1995 Apr; 73(4):675-9. PubMed ID: 7495077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
    Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
    Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human factor IX and factor IXa.
    Bajaj SP; Birktoft JJ
    Methods Enzymol; 1993; 222():96-128. PubMed ID: 8412817
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunoaffinity purification of factor IX (Christmas factor) by using conformation-specific antibodies directed against the factor IX-metal complex.
    Liebman HA; Limentani SA; Furie BC; Furie B
    Proc Natl Acad Sci U S A; 1985 Jun; 82(11):3879-83. PubMed ID: 2408269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate.
    Thomas DP; Hampton KK; Dasani H; Lee CA; Giangrande PL; Harman C; Lee ML; Preston FE
    Br J Haematol; 1994 Aug; 87(4):782-8. PubMed ID: 7986719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of highly purified clotting factor IX by a combination of different chromatographic methods.
    Hoffer L; Schwinn H; Josić D
    J Chromatogr A; 1999 Jun; 844(1-2):119-28. PubMed ID: 10399328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purification of human copper, zinc superoxide dismutase by copper chelate affinity chromatography.
    Weselake RJ; Chesney SL; Petkau A; Friesen AD
    Anal Biochem; 1986 May; 155(1):193-7. PubMed ID: 3717556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation of plasma proteins from the clotting cascade by heparin affinity chromatography.
    Josić D; Bal F; Schwinn H
    J Chromatogr; 1993 Feb; 632(1-2):1-10. PubMed ID: 8454710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Removal of parvovirus and hepatitis A virus by metal chelate affinity chromatography during the preparation of Replenine: a high-purity factor IX concentrate.
    Roberts PL
    Vox Sang; 1996; 71(2):129-30. PubMed ID: 8873426
    [No Abstract]   [Full Text] [Related]  

  • 15. Chromatographic purification and properties of a therapeutic human protein C concentrate.
    Radosevich M; Zhou FL; Huart JJ; Burnouf T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jun; 790(1-2):199-207. PubMed ID: 12767332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and properties of a therapeutic factor IX concentrate.
    Suomela H; Myllylä G; Raaska E
    Vox Sang; 1977 Jul; 33(1):37-50. PubMed ID: 883244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity of factor IX BM. Difference of cleavage sites by factor XIa and Ca2+ in factor IX Kashihara, factor IX Nagoya and factor IX Niigata.
    Yoshioka A; Ohkubo Y; Nishimura T; Tanaka I; Fukui H; Ogata K; Kamiya T; Takahashi H
    Thromb Res; 1986 Jun; 42(5):595-604. PubMed ID: 3487139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purification of human factor IX by chromatography of a coagulation factor concentrate.
    Suomela H
    Thromb Haemost; 1976 Feb; 35(1):211-21. PubMed ID: 989188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homologous human blood protein separation using immobilized metal affinity chromatography: protein C separation from prothrombin with application to the separation of factor IX and prothrombin.
    Wu H; Bruley DF
    Biotechnol Prog; 1999; 15(5):928-31. PubMed ID: 10514264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoaffinity purification of factor IX from commercial concentrates and infusion studies in animals.
    Smith KJ
    Blood; 1988 Oct; 72(4):1269-77. PubMed ID: 3262386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.